 PETAH TIKVA, Israel, Nov. 04, 2020 GLOBE NEWSWIRE -- PolyPid Ltd. Nasdaq: PYPD, a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today announced that it will present at two investor conferences in November. Details on the presentations can be found below. The company will also participate in one-on-one investor meetings at the AGP Virtual Healthcare Symposium 2020 on Thursday, November 19. 